Literature DB >> 30037941

EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.

Kyriaki Tzogani, Paula Van Hennik, Ita Walsh, Pieter De Graeff, Annika Folin, Jan Sjöberg, Tomas Salmonson, Jonas Bergh, Edward Laane, Heinz Ludwig, Christian Gisselbrecht, Francesco Pignatti.   

Abstract

Entities:  

Year:  2018        PMID: 30037941      PMCID: PMC6058342          DOI: 10.1634/theoncologist.2017-0301erratum

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
2018;23:631–636; first published on November 30, 2017; http://dx.doi.org/10.1634/theoncologist.2017‐0301 A correction was made to a sentence in the Clinical Safety section of this article to clarify the names of the two arms being compared. The online version of this article was updated, and the corrected sentence reads as follows: More patients required hospitalization due to AEs in the PAN + BTZ + Dez arm (55%) than in the PBO + BTZ + Dex arm (37%).
  1 in total

1.  Epigenetic silencing of E-cadherin gene induced by lncRNA MALAT-1 in acute myeloid leukaemia.

Authors:  Jinlong Huang; Jingping Fang; Qinchang Chen; Jinyuan Chen; Jianzhen Shen
Journal:  J Clin Lab Anal       Date:  2022-06-23       Impact factor: 3.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.